IKNA / Ikena Oncology, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

INMAGENE MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

EX-99.3 Exhibit 99.3 INMAGENE MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS On July 25, 2025, the Delaware corporation formerly known as “Ikena Oncology, Inc.” completed its previously announced merger with Inmagene Biopharmaceuticals, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands (“Inmagene”), in a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025 IMAGENEBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation)

INMAGENE BIOPHARMACEUTICALS INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Page(s) Condensed Consolidated Financial Statements Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 F-2 Condensed Consolidated Statements

EX-99.4 Exhibit 99.4 INMAGENE BIOPHARMACEUTICALS INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Page(s) Condensed Consolidated Financial Statements Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 F-2 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2025 and 2024 F-3 Condensed Consolidated Statem

August 5, 2025

EX-16.1 Exhibit 16.1 August 5, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated August 5, 2025 of ImageneBio, Inc. and are in agreement with the statements contained in the first, second, third and fourth paragraphs under (a) Dismissal of Independent Registered Public Accounting Firm. We have no basis to agree o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2025 IMAGENEBIO, INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2025 IMAGENEBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission File Nu

IMAGENEBIO, INC. 2025 EQUITY INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: JULY 28, 2025

EX-99.1 Exhibit 99.1 IMAGENEBIO, INC. 2025 EQUITY INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: JULY 28, 2025 1. GENERAL. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Eligible Employees to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 IMAGENEBIO, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 IMAGENEBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission File Num

EMPLOYMENT AGREEMENT

Exhibit 10.10 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), effective on April 25, 2022 (the “Effective Date”), is made and entered into by and between Ikena Oncology, Inc., a Delaware corporation (the “Company”), and Jotin Marango (the “Executive”) WHEREAS, the Company desires to continue to employ the Executive and the Executive desires to continue to be employed by the Comp

COMPANY CONTINGENT VALUE RIGHTS AGREEMENT

EX-10.3 Exhibit 10.3 COMPANY CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of July 25, 2025, is entered into by and among Ikena Oncology, Inc., a Delaware corporation (“Insight”), Inmagene Biopharmaceuticals, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands (the “Company”), and Computer

CERTIFICATE OF AMENDMENT FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION IKENA ONCOLOGY, INC.

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IKENA ONCOLOGY, INC. IKENA ONCOLOGY, INC., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Ikena Oncology, Inc. The date of the filing of its original Certificate of Incorporation with the

ImageneBio, Inc. 2025 Employee Stock Purchase Plan Adopted by the Board of Directors: December 12, 2024 Approved by the Stockholders: July 15, 2025 Effective Date: July 26, 2025

Exhibit 10.23 ImageneBio, Inc. 2025 Employee Stock Purchase Plan Adopted by the Board of Directors: December 12, 2024 Approved by the Stockholders: July 15, 2025 Effective Date: July 26, 2025 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits

REGISTRATION RIGHTS AGREEMENT

EX-10.8 Exhibit 10.8 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made as of July 25, 2025 by and among ImageneBio, Inc. (formerly Ikena Oncology, Inc.), (the “Company”), and the several purchasers signatory hereto (each, a “Purchaser” and collectively, the “Purchasers”). RECITALS WHEREAS, the Company and the Purchasers are parties to a Subscription Agreeme

EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTIONS ASSIGNMENT AGREEMENT

EX-10.9 Exhibit 10.9 July 23, 2025 Kristin Yarema, Ph.D. [***] Re: Offer of Employment Dear Dr. Yarema: We are pleased to offer you at-will employment in the position of Chief Executive Officer (“CEO”) of Ikena Oncology, Inc. (to be renamed ImageneBio, Inc. upon consummation of the Merger, the “Company”) on the terms and conditions set forth in this letter agreement (the “Agreement”). The “Merger”

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below shall have the same meaning as terms defined and included in the Ikena’s proxy statement/prospectus filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 11, 2025. As previously announced, on December 23, 2024, Ikena Oncology, Inc., a Delaware corporation (“Ikena”), Insight M

INSIGHT CONTINGENT VALUE RIGHTS AGREEMENT

Exhibit 10.2 INSIGHT CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of July 25, 2025, is entered into by and among Ikena Oncology, Inc., a Delaware corporation (“Insight”), and Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company (collectively, a

IMAGENEBIO, INC. RSU AWARD GRANT NOTICE (2025 EQUITY INCENTIVE PLAN)

EX-10.22 Exhibit 10.22 IMAGENEBIO, INC. RSU AWARD GRANT NOTICE (2025 EQUITY INCENTIVE PLAN) ImageneBio, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company’s 2

Disclaimer This presentation contains “forward-looking statements” under the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ImageneBio, Inc.’s (“Imagene’s”) actual results may differ from their expect

EX-99.1 Exhibit 99.1 Corporate Overview July 2025 Disclaimer This presentation contains “forward-looking statements” under the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ImageneBio, Inc.’s (“Imagene’s”) actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking sta

CERTIFICATE OF AMENDMENT FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION IKENA ONCOLOGY, INC.

EX-3.2 Exhibit 3.2 CERTIFICATE OF AMENDMENT TO FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IKENA ONCOLOGY, INC. Ikena Oncology, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: FIRST: The name of this corporation is Ikena Oncology, Inc., and the date on w

IMAGENEBIO, INC. STOCK OPTION GRANT NOTICE (2025 EQUITY INCENTIVE PLAN)

Exhibit 10.21 IMAGENEBIO, INC. STOCK OPTION GRANT NOTICE (2025 EQUITY INCENTIVE PLAN) ImageneBio, Inc. (the “Company”), pursuant to the Company’s 2025 Equity Incentive Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number of shares of the Common Stock set forth below (the “Option”). Your Option is subject to all of the terms and conditions as set forth herein and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025 IMAGENEBIO, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025 IMAGENEBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission File Num

IMAGENEBIO, INC. 2025 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: DECEMBER 12, 2024 APPROVED BY THE STOCKHOLDERS: JULY 15, 2025

Exhibit 10.20 IMAGENEBIO, INC. 2025 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: DECEMBER 12, 2024 APPROVED BY THE STOCKHOLDERS: JULY 15, 2025 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) any Returning Shares will

July 23, 2025

Exhibit 10.18 July 23, 2025 Jonathan Jian Wang, Ph.D., MBA Via email to [***] Re: Separation Agreement Dear Dr. Wang: This letter sets forth the substance of the separation agreement (the “Agreement”) that Inmagene Biopharmaceuticals (the “Company”) is offering to you to aid in your employment transition. 1. SEPARATION. As you know, the Company has entered into that certain Agreement and Plan of M

TRANSITION SERVICES AGREEMENT dated as of July 25, 2025 by and between Miragene Inc Inmagene Biopharmaceuticals

Exhibit 10.4 TRANSITION SERVICES AGREEMENT dated as of July 25, 2025 by and between Miragene Inc and Inmagene Biopharmaceuticals TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 1.1 Definitions 1 1.2 Other Definitional and Interpretative Provisions 2 ARTICLE 2 SERVICES 2 2.1 Provision of Services 2 2.2 Discontinuation of Services 4 2.3 Compliance with Law; Consents 4 ARTICLE 3 SERVICE COSTS; OTHER C

EMPLOYMENT AGREEMENT

EX-10.14 Exhibit 10.14 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made between Ikena Oncology, Inc., a Delaware corporation (the “Company”), and Mark Manfredi, Ph.D. (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 19

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025 IMAGENEBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission File Num

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbo

EX-99.1 Exhibit 99.1 Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of no

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission File

Amendment to Employment Agreement, dated July 15, 2025, by and between the Registrant and Jotin Marango, M.D., Ph.D.

Exhibit 10.4 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into effective as of July 15, 2025 (the “Amendment Date”), by and between Ikena Oncology, Inc., a Delaware corporation (the “Company”), and Jotin Marango (the “Executive” and, together with the Company, the “Parties”). This is an amendment to that certain Employment Agreemen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40287 IKENA ONCOLOGY, INC.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2025 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2025 IKENA ONCOLOGY, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2025 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2025 IKENA ONCOLOGY, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2025 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission File

Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals Combined Company to Trade on Nasdaq Under Ticker “IMA” Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock

EX-99.1 Exhibit 99.1 Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals Combined Company to Trade on Nasdaq Under Ticker “IMA” Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock BOSTON, MA and SAN DIEGO, CA, July 15, 2025 — Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) today announced the results of the annual meeting of its stockholders held o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2025 IKENA ONCOLOGY, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2025 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission File

Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals

Exhibit 99.1 Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals BOSTON, July 11, 2025, – Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” the “Company”) today announced that Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co. (“Glass Lewis”) recommend that stockholders vote FOR the issuance of shares in con

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2025 IKENA ONCOLOGY, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2025 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2025 IKENA ONCOLOGY, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2025 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2025 IKENA ONCOLOGY, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2025 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission File

Inmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of

EX-99.1 Exhibit 99.1 Inmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of IMG-007, a Nondepleting Anti-OX40 mAb with an Extended Half-life, in Patients with Moderate-to-Severe Atopic Dermatitis • The ADAPTIVE Phase 2b trial evaluates multiple dose regimens of IMG-007 in patients with moderate-to-severe atopic dermatitis • Topline data expected in the fourth quarter of 2026 San Diego, CA,

PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT

TABLE OF CONTENTS Filed pursuant to rule 424(b)(3) Registration No. 333-285881                         PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT To the Stockholders of Ikena Oncology, Inc., Ikena Oncology, Inc., a Delaware corporation (“Ikena”), and Inmagene Biopharmaceuticals, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands (“Inmagene”),

Ikena Oncology, Inc. 645 Summer Street, Suite 101 Boston, MA 02210

Ikena Oncology, Inc. 645 Summer Street, Suite 101 Boston, MA 02210 June 10, 2025 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street NE Washington, D.C. 20549-3628 Attention: Ms. Christine Torney Ms. Lynn Dicker Mr. Daniel Crawford Mr. Alan Campbell Re: Ikena Oncology, Inc. Acceleration Request for Registration Statement on Form S-

As filed with the Securities and Exchange Commission on June 9, 2025

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 9, 2025 No.

CONSENT OF LEERINK PARTNERS LLC

Exhibit 99.2 CONSENT OF LEERINK PARTNERS LLC We hereby consent to the use of our opinion letter dated December 23, 2024, to the Board of Directors of Ikena Oncology, Inc., included as Annex B to the proxy statement/prospectus which forms a part of Amendment No. 5 to the Registration Statement on Form S-4 of Ikena Oncology, Inc., to be filed on the date hereof, and to the references to such opinion

*****

Goodwin Procter 100 Northern Ave. Boston, MA 02210 VIA EDGAR June 9, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3628 Attention: Christine Torney, Lynn Dicker, Daniel Crawford and Alan Campbell Re: Ikena Oncology, Inc. Amendment No. 4 to Registration Statement on Form S-4 Filed May 30, 2025

As filed with the Securities and Exchange Commission on May 30, 2025

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 30, 2025 No.

CONSENT TO BE NAMED AS A DIRECTOR NOMINEE

Exhibit 99.3 CONSENT TO BE NAMED AS A DIRECTOR NOMINEE In connection with the filing by Ikena Oncology, Inc., a Delaware corporation (the “Company”), of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to

CONSENT OF LEERINK PARTNERS LLC

Exhibit 99.2 CONSENT OF LEERINK PARTNERS LLC We hereby consent to the use of our opinion letter dated December 23, 2024, to the Board of Directors of Ikena Oncology, Inc., included as Annex B to the proxy statement/prospectus which forms a part of Amendment No. 4 to the Registration Statement on Form S-4 of Ikena Oncology, Inc., to be filed on the date hereof, and to the references to such opinion

CONSENT TO BE NAMED AS A DIRECTOR NOMINEE

Exhibit 99.4 CONSENT TO BE NAMED AS A DIRECTOR NOMINEE In connection with the filing by Ikena Oncology, Inc., a Delaware corporation (the “Company”), of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to

CONSENT OF LEERINK PARTNERS LLC

Exhibit 99.2 CONSENT OF LEERINK PARTNERS LLC We hereby consent to the use of our opinion letter dated December 23, 2024, to the Board of Directors of Ikena Oncology, Inc., included as Annex B to the proxy statement/prospectus which forms a part of Amendment No. 3 to the Registration Statement on Form S-4 of Ikena Oncology, Inc., to be filed on the date hereof, and to the references to such opinion

CONSENT TO BE NAMED AS A DIRECTOR NOMINEE

Exhibit 99.5 CONSENT TO BE NAMED AS A DIRECTOR NOMINEE In connection with the filing by Ikena Oncology, Inc., a Delaware corporation (the “Company”), of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to

As filed with the Securities and Exchange Commission on May 20, 2025

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 20, 2025 No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40287 IKENA ONCOLOGY, INC.

CONSENT OF LEERINK PARTNERS LLC

Exhibit 99.2 CONSENT OF LEERINK PARTNERS LLC We hereby consent to the use of our opinion letter dated December 23, 2024, to the Board of Directors of Ikena Oncology, Inc., included as Annex B to the proxy statement/prospectus which forms a part of Amendment No. 2 to the Registration Statement on Form S-4 of Ikena Oncology, Inc., to be filed on the date hereof, and to the references to such opinion

*****

Goodwin Procter 100 Northern Ave. Boston, MA 02210 VIA EDGAR May 7, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3628 Attention: Christine Torney, Lynn Dicker, Daniel Crawford and Alan Campbell Re: Ikena Oncology, Inc. Amendment No. 1 to Registration Statement on Form S-4 Filed April 21, 2025

As filed with the Securities and Exchange Commission on May 7, 2025

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 7, 2025 No.

*****

Goodwin Procter 100 Northern Ave. Boston, MA 02210 VIA EDGAR April 21, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3628 Attention: Christine Torney, Lynn Dicker, Daniel Crawford and Alan Campbell Re: Ikena Oncology, Inc. Registration Statement on Form S-4 Filed March 18, 2025 File No. 333-28

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT INMAGENE BIOPHARMACEUTICALS TREATS AS PRIVATE AND CONFIDENTIAL. CELL LINE LICENSE AGREEMENT P

Exhibit 10.12 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT INMAGENE BIOPHARMACEUTICALS TREATS AS PRIVATE AND CONFIDENTIAL. CELL LINE LICENSE AGREEMENT Project ID: INMA-20210226 This Cell Line License Agreement (“Agreement”), effective as of Feb 26th, 2021 (“EFFECTIVE DATE”), is entered a

CONSENT OF LEERINK PARTNERS LLC

Exhibit 99.2 CONSENT OF LEERINK PARTNERS LLC We hereby consent to the use of our opinion letter dated December 23, 2024, to the Board of Directors of Ikena Oncology, Inc., included as Annex B to the proxy statement/prospectus which forms a part of Amendment No. 1 to the Registration Statement on Form S-4 of Ikena Oncology, Inc., to be filed on the date hereof, and to the references to such opinion

As filed with the Securities and Exchange Commission on April 21, 2025

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 21, 2025 No.

Severance Rights Agreement

Exhibit 10.9 Severance Rights Agreement This Severance Rights Agreement (the “Agreement”) is made effective as of October 8, 2024 (the “Effective Date”), by and between Inmagene Biopharmaceuticals (the “Company”) and Yufang Lu (“Executive”). 1. Severance Benefits. If the Company terminates Executive’s employment without Cause (as defined below) or Executive resigns employment for Good Reason (as d

1

EXHIBIT 10.6 December 11, 2022 Dear Yufang, We are pleased to extend to you an offer of employment with lnmagene LLC. This offer is for an exempt, fulltime position as Chief Medical Officer (CMO). Your projected starting date will be February 14, 2023. You will be compensated at a rate of$ 432,000.00 annually and will be entitled to a year-end performance-based bonus (target at 30% of the base sal

Severance Rights Agreement

Exhibit 10.8 Severance Rights Agreement This Severance Rights Agreement (the “Agreement”) is made effective as of March 6, 2025 (the “Effective Date”), by and between Inmagene Biopharmaceuticals (the “Company”) and Jonathan Jian Wang (“Executive”). 1. Severance Benefits. If the Company terminates Executive’s employment without Cause (as defined below) or Executive resigns employment for Good Reaso

October 10, 2023

EXHIBIT 10.7 October 10, 2023 Dear Erin, We are pleased to extend to you an offer of employment with Inmagene LLC. This offer is for an exempt, full-time position as Vice President and Controller. Your projected starting date will be as soon as possible, but no later than October 23, 2023. You will be compensated at a rate of $ 300,000.00 annually and will be entitled to a year-end performance-bas

Calculation of Filing Fee Table Form S-4 (Form Type) IKENA ONCOLOGY, INC. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Table Form S-4 (Form Type) IKENA ONCOLOGY, INC.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT INMAGENE BIOPHARMACEUTICALS TREATS AS PRIVATE AND CONFIDENTIAL. COLLABORATION, OPTION AND LIC

Exhibit 10.11 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT INMAGENE BIOPHARMACEUTICALS TREATS AS PRIVATE AND CONFIDENTIAL. COLLABORATION, OPTION AND LICENSE AGREEMENT BY AND BETWEEN INMAGENE BIOPHARMACEUTICALS AND 和记黄埔医药（上海）有限公司HUTCHISON MEDIPHARMA LIMITED TABLE OF CONTENTS Article I DEF

Inmagene Biopharmaceuticals 2019 STOCK INCENTIVE PLAN

Exhibit 10.1 Inmagene Biopharmaceuticals 2019 STOCK INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company’s business. 2. Definitions. The following definitions shall apply as used herein and in the individual Award Ag

CONSENT OF LEERINK PARTNERS LLC

Exhibit 99.2 CONSENT OF LEERINK PARTNERS LLC We hereby consent to the use of our opinion letter dated December 23, 2024, to the Board of Directors of Ikena Oncology, Inc., included as Annex B to the proxy statement/prospectus which forms a part of the Registration Statement on Form S-4 of Ikena Oncology, Inc., to be filed on the date hereof, and to the references to such opinion in such proxy stat

Severance Rights Agreement

Exhibit 10.10 Severance Rights Agreement This Severance Rights Agreement (the “Agreement”) is made effective as of October 21, 2024 (the “Effective Date”), by and between Inmagene Biopharmaceuticals (the “Company”) and Erin Butler (“Executive”). 1. Severance Benefits. If the Company terminates Executive’s employment without Cause (as defined below) or Executive resigns employment for Good Reason (

December 26, 2022

Exhibit 10.5 December 26, 2022 Jonathan Wang Dear Jon, We are pleased to extend to you an offer of employment with lnmagene LLC. This offer is for an exempt, fulltime position as CEO, reporting into Board of Directors. Your projected starting date will be January 1st, 2023. You will be compensated at a rate of $330,000 annually, and will be entitled to a year-end performance-based bonus (target at

INDEMNIFICATION AGREEMENT

Exhibit 10.4 INDEMNIFICATION AGREEMENT This Indemnification Agreement is dated as of , 20[] (this “Agreement”) and is between ImageneBio, Inc., a Delaware corporation (the “Company”), and [Name] (“Indemnitee”). Background The Company believes that in order to attract and retain highly competent persons to serve as directors or in other capacities, including as officers, it must provide such person

As filed with the Securities and Exchange Commission on March 18, 2025

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 18, 2025 No.

Separation Agreement, dated February 13, 2025, by and between the Registrant and Caroline Germa, M.D. (incorporated by reference to Exhibit 10.18 to the Registrant’s Annual Report on Form 10-K (File No. 001-40287) filed with the SEC on March 6, 2025).

Exhibit 10.18 February 13, 2025 PERSONAL AND CONFIDENTIAL M. Caroline Germa, M.D. Re: Separation Agreement Dear Caroline: This letter confirms that your employment with Ikena Oncology, Inc. (the “Company”) will be ending. This letter is a “Notice of Termination” pursuant to Sections 3(d) and 4(a) of the Employment Agreement between the Company and you (the “Employment Agreement”). Your employment

Consulting Agreement, dated February 4, 2025, by and between the Registrant and Caroline Germa, M.D. (incorporated by reference to Exhibit 10.17 to the Registrant’s Annual Report on Form 10-K (File No. 001-40287) filed with the SEC on March 6, 2025).

Exhibit 10.17 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. Ikena oncology, Inc. Consulting Agreement This Consulting Agreement (the “Agreement”), made and effectiv

Retention Bonus Agreement, dated February 22, 2025, by and between the Registrant and Jotin Marango, M.D., Ph.D. (incorporated by reference to Exhibit 10.19 to the Registrant’s Annual Report on Form 10-K (File No. 001-40287) filed with the SEC on March 6, 2025).

Exhibit 10.19 February 18, 2025 To: Jotin Marango CC: Personnel File RE: January 2025 Retention Cash Bonus Dear Jotin, I am delighted to share that in recognition of your ongoing dedication and support, we intend to award you a one-time discretionary bonus of $70,000 (the “Retention Bonus”), to be paid within three business days following the earliest to occur of (1) the closing of the transaction

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40287 IKENA ONCOLOGY,

Filed by Ikena Oncology, Inc.

425 Filed by Ikena Oncology, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Ikena Oncology, Inc. Commission File No.: 001-40287 Date: January 10, 2025 Inmagene Reports Positive Topline Results of IMG-007, a Nondepleting Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Tr

Loan and Security Agreement, dated as of December 23, 2024, by and between Ikena and Inmagene

Exhibit 10.3 INMAGENE BIOPHARMACEUTICALS, AS BORROWER AND IKENA ONCOLOGY, INC., AS LENDER LOAN AND SECURITY AGREEMENT Exhibit 10.3 This LOAN AND SECURITY AGREEMENT is entered into as of December 23, 2024, by and among Inmagene Biopharmaceuticals, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands (the “Borrower”), the Guarantors from time to t

Form of Inmagene Biopharmaceuticals Support Agreement (Incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K (File No. 001-40287) filed with the SEC on December 23, 2024).

Exhibit 10.4 INMAGENE BIOPHARMACEUTICALS SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”), dated as of December 23, 2024, is made by and among Ikena Oncology, Inc., a Delaware corporation (“Insight”), Inmagene Biopharmaceuticals, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands (the “Company”), and the undersigned holders (each a

Form of Lock-Up Agreement

Exhibit 10.6 LOCK-UP AGREEMENT [DATE] Ikena Oncology, Inc. 645 Summer Street, Suite 101 Boston, MA, 02210 Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that Ikena Oncology, Inc., a Delaware corporation (“Insight”), has entered into an Agreement and Plan of Merger, dated as of December 23, 2024 (as the same may be amended from time

Form of Inmagene CVR Agreement

Exhibit 10.2 FORM OF COMPANY CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of [•], is entered into by and among Ikena Oncology, Inc., a Delaware corporation (“Insight”), and Computershare Inc., a Delaware corporation (“Computershare”), and its wholly owned subsidiary, Computershare Trust Company, N.A., a federally chartered trust company (col

Subscription Agreement, dated as of December 23, 2024, by and among Ikena and certain parties thereto

Exhibit 10.7 SUBSCRIPTION AGREEMENT This Subscription Agreement (this “Agreement”) is made and entered into as of December 23, 2024 (the “Effective Date”) by and among Ikena Oncology, Inc., a Delaware corporation (the “Company”), and the purchasers listed on the signature pages hereto (each a “Purchaser” and together the “Purchasers”). Certain terms used and not otherwise defined in the text of th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 IKENA ONCOLOGY,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission

Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended h

Exhibit 99.1 Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function The transaction is expected to result in approximately $175 million to support further development

Regulation FD Disclosure, Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission

Agreement and Plan of Merger, dated December 23, 2024, by and among the Registrant, Insight Merger Sub I, Insight Merger Sub II, and Inmagene Biopharmaceuticals (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40287) filed with the SEC on December 23, 2024).

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among: IKENA ONCOLOGY, INC.; INSIGHT MERGER SUB I; INSIGHT MERGER SUB II; and INMAGENE BIOPHARMACEUTICALS Dated as of December 23, 2024 Exhibit 2.1 TABLE OF CONTENTS Page Section 1. Definitions and Interpretative Provisions 3 1.1 Definitions 3 1.2 Other Definitional and Interpretative Provisions 21 Section 2. Description of Transaction 22 2.1 The Merger 22

Form of Ikena Oncology, Inc. Support Agreement (Incorporated by reference to Exhibit 10.5 to the Registrant’s Current Report on Form 8-K (File No. 001-40287) filed with the SEC on December 23, 2024).

Exhibit 10.5 Ikena Oncology, Inc. SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”), dated as of December 23, 2024, is made by and among Ikena Oncology, Inc., a Delaware corporation (“Insight”), Inmagene Biopharmaceuticals, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands (the “Company”), and the undersigned holders (each a “Stockh

Form of Ikena CVR Agreement

Exhibit 10.1 FORM OF INSIGHT CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of [•], is entered into by and among Ikena Oncology, Inc., a Delaware corporation (“Insight”), and Computershare Inc., a Delaware corporation (“Computershare”), and its wholly owned subsidiary, Computershare Trust Company, N.A., a federally chartered trust company (col

Investor Presentation, dated November 2024

EX-99.2 Corporate Overview November 2024 Exhibit 99.2 Disclaimer This presentation and the accompanying slides (this “Presentation”) which have been prepared by Inmagene Biopharmaceuticals (“Inmagene,” the “Company” or together with its subsidiaries, collectively referred to as the “Group”) are being delivered to a limited number of parties for discussion purposes only, and shall not form the basi

IKNA / Ikena Oncology, Inc. / Blue Owl Capital Holdings LP - SC 13G Passive Investment

SC 13G 1 ef20038675sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Ikena Oncology Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45175G108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the

IKNA / Ikena Oncology, Inc. / BRISTOL MYERS SQUIBB CO - SC 13G/A Passive Investment

SC 13G/A 1 ef20038543sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Ikena Oncology, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45175G108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the app

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40287 IKENA ONCOLOGY, INC.

Retention Award Agreement, dated July 1, 2024, by and between the Registrant and Mark Manfredi, Ph.D.

Exhibit 10.1 July 1, 2024 To: Mark Manfredi CC: Personnel File RE: July 2024 Retention Cash Bonus Dear Mark, I am delighted to share that in recognition of your ongoing dedication and support, we intend to award you a one-time discretionary bonus of $300,000.00. This bonus will be paid within two business days of the closure of a material transaction involving Ikena, as determined by Ikena’s board

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40287 IKENA ONCOLOGY, INC.

Retention Award Agreement, dated July 1, 2024, by and between the Registrant and Jotin Marango, M.D., Ph.D

Exhibit 10.2 July 1, 2024 To: Joti Marango CC: Personnel File RE: July 2024 Retention Cash Bonus Dear Joti, I am delighted to share that in recognition of your ongoing dedication and support, we intend to award you a one-time discretionary bonus of $250,000.00. This bonus will be paid in three installments: $82,500.00 will be paid to you on July 15, 2024, a subsequent $82,500.00 will be paid at th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2024 IKENA ONCOLOGY, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2024 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission File

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2024 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission File

Ikena Oncology Announces Strategic Update Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strate

Exhibit 99.1 Ikena Oncology Announces Strategic Update Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024, – Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced

Forward Looking Statement Any statements in presentation other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans and prospects fo

Exhibit 99.2 ® Corporate Presentation Second Quarter 2024 Confidential 1 Forward Looking Statement Any statements in presentation other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans and prospects for Ikena Oncology, Inc. including statements regarding the market and therapeu

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40287 IKENA ONCOLOGY, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant   ☒ Filed by a Party other than the Registr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant   ☒ Filed by a Party other than the Registrant   ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION   Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, fo

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Ikena Oncology, Inc.

As filed with the Securities and Exchange Commission on March 12, 2024

As filed with the Securities and Exchange Commission on March 12, 2024 Registration No.

Compensation Recovery Policy.

EXHIBIT 97.1 IKENA ONCOLOGY, INC. COMPENSATION RECOVERY POLICY Adopted as of September 19, 2023 Ikena Oncology, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40287 IKENA ONCOLOGY,

Insider Trading Policy.

EXHIBIT 19.1 IKENA ONCOLOGY, INC. AMENDED AND RESTATED INSIDER TRADING POLICY This memorandum sets forth the policy of Ikena Oncology, Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Amended and Restated Insider Trading Policy (this “Insider Trading Policy”) is de

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission

Consulting Agreement, dated February 20, 2024, by and between Sergio Santillana and Ikena Oncology, Inc.

Exhibit 10.1 IKENA ONCOLOGY, INC. CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”), made and effective as of this March 6, 2024 (the “Effective Date”) is entered into by Ikena Oncology, Inc. a Delaware corporation (the “Company”) having an office at 645 Summer Street, Suite 101, Boston, MA 02210, and SLSS Consulting, LLC at [***] (the “Consultant”). WHEREAS, the Company and the Con

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise Dr. Germa will drive clinical d

Exhibit 99.1 Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise Dr. Germa will drive clinical development strategy and oversee the execution of targeted oncology programs, IK-930 and IK-595 Sergio Santillana, M.D., M.Sc., MBA resign

IKNA / Ikena Oncology, Inc. / Omega Fund VI, L.P. - SC 13G/A Passive Investment

SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1) Ikena Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45175G108 (CUSIP Number) December 31, 2023 (Date of Event Which

IKNA / Ikena Oncology, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm243573d7sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 3)* Ikena Oncology, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (the “Shares”) (Tit

IKNA / Ikena Oncology, Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 3 TO SCHEDULE 13G Passive Investment

SC 13G/A 1 sc13ga307422ikna02142024.htm AMENDMENT NO. 3 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 Ikena Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0

Regulation FD Disclosure, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission F

Ikena Oncology Outlines Key Priorities and Provides Corporate Updates IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety evaluation window Focused

Exhibit 99.1 Ikena Oncology Outlines Key Priorities and Provides Corporate Updates IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety evaluation window Focused execution on core targeted oncology clinical programs; organizational reallocation of resources from exploratory discovery to clinical de

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission F

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results Favorable safety profile in dose escalation shown to date; selective TEAD1 inhibition with IK-93

EXHIBIT 99.1 Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results Favorable safety profile in dose escalation shown to date; selective TEAD1 inhibition with IK-930 resulted in minimal treatment-related proteinuria without any dose reductions or treatment interruptions Encouraging signs of clinical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40287 IKENA ONCOLOGY, INC.

IKNA / Ikena Oncology Inc / GILEAD SCIENCES INC - OCT 2023 FILING, IKENA ONC AS ISSUER FOR GILEAD SCIENCES, THE REPORTING PERSON Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Ikena Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45175G108 (CUSIP Number) October 11, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2023 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D

JOINT FILING AGREEMENT

EX-99.1 2 ss2516138ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 3 to the Statement on Schedule 13D, dated August 4, 2023, with respect to the common stock of Ikena Oncology, Inc., is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amen

IKNA / Ikena Oncology Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) Ikena Oncology, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 45175G108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Teleph

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant  ☐ Check the appropriate box: ☒ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  ☐ D

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 2 to the Statement on Schedule 13D, dated August 4, 2023, with respect to the common stock of Ikena Oncology, Inc., is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible

IKNA / Ikena Oncology Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Ikena Oncology, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 45175G108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Teleph

5,954,091 Shares Common Stock Offered by the Selling Stockholders

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-274072 PROSPECTUS 5,954,091 Shares Common Stock Offered by the Selling Stockholders This prospectus relates to the proposed resale or other disposition by the selling stockholders identified herein (the “Selling Stockholders”) of (i) 1,647,531 shares of our voting common stock, par value $0.001 per share (“Common Stock” and su

September 6, 2023

September 6, 2023 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Ikena Oncology, Inc.

As filed with the Securities and Exchange Commission on August 18, 2023

S-3 Table of Contents As filed with the Securities and Exchange Commission on August 18, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40287 IKENA ONCOLOGY, INC.

Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40287) filed with the SEC on August 7, 2023).

EX-3.1 Exhibit 3.1 IKENA ONCOLOGY, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Ikena Oncology, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted

Agreement and Plan of Merger by and among the Registrant, Portsmouth Merger Sub I, Inc., Portsmouth Merger Sub II, LLC, Pionyr Immunotherapeutics, Inc. and Fortis Advisors LLC, as securityholder agent, dated August 4, 2023 (Incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40287 filed with the SEC on August 7, 2023).

EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among: IKENA ONCOLOGY, INC.; PORTSMOUTH MERGER SUB I, INC; PORTSMOUTH MERGER SUB II, LLC; PIONYR IMMUNOTHERAPEUTICS, INC. And FORTIS ADVISORS LLC, as the Securityholder Agent Dated as of August 4, 2023 TABLE OF CONTENTS Page Section 1. Definitions and Interpretative Provisions 2 1.1 Definitions 2 1.2 Other Definitional and Interpretative Provisions 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 (August 4, 2023) I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 (August 4, 2023) IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena’s targeted oncology pipeline

EX-99.1 Exhibit 99.1 Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena’s targeted oncology pipeline BOSTON, MA and SOUTH SAN FRANCISCO, CA, August 07, 2023 — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new

Contingent Value Rights Agreement, by and between the Registrant and Computershare Trust Company N.A, as rights agent, dated August 4, 2023 (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40287) filed with the SEC on August 7, 2023).

EX-10.1 Exhibit 10.1 CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of August 4, 2023, is entered into by and among Ikena Oncology, Inc., a Delaware corporation (“Ikena”) and Computershare Inc., a Delaware corporation and its affiliate Computershare Trust Company, N.A., a federally chartered trust company, collectively, as initial Rights Agent

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 IKENA ONCOLOGY, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 IKENA ONCOLOGY, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission File

6,110,000 Shares Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-264517 PROSPECTUS SUPPLEMENT (To prospectus dated May 5, 2022) 6,110,000 Shares Common Stock We are offering 6,110,000 shares of our common stock, $0.001 par value per share, at a public offering price of $6.550 per share. Our common stock is listed on The Nasdaq Global Market under the symbol “IKNA.” On May 12, 2023, th

Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline Lead targeted oncology program in Hippo pathway, IK-930, continues to advance through dose escalation with no dose-limiting toxi

EX-99.1 Exhibit 99.1 Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline Lead targeted oncology program in Hippo pathway, IK-930, continues to advance through dose escalation with no dose-limiting toxicities observed to-date Preclinical data at AACR Annual Meeting demonstrated IK-930 TEAD1 selectivity with equivalent activity to

Ikena Oncology Announces $40 Million Underwritten Offering

EX-99.3 Exhibit 99.3 Ikena Oncology Announces $40 Million Underwritten Offering BOSTON—May 15, 2023 —Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, announced today the pricing of an underwritten offering of 6,110,000 shares of common stock (the “Shares”) at an offering price of $6.550 per share. The g

Developing Biology-Driven Medicines and Expanding the Impact of Targeted Oncology • Multiple ongoing clinical trials with expected data readouts in the next 12 months • Leaders in Hippo pathway with clinical stage TEAD1 inhibitor IK-930 • Initial mon

EX-99.2 Exhibit 99.2 Corporate Presentation May 2023 Confidential 1 Developing Biology-Driven Medicines and Expanding the Impact of Targeted Oncology • Multiple ongoing clinical trials with expected data readouts in the next 12 months • Leaders in Hippo pathway with clinical stage TEAD1 inhibitor IK-930 • Initial monotherapy dose escalation data in all comers, mesothelioma, We develop differentiat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40287 IKENA ONCOLOGY, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 IKENA ONCOLOGY, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission File

Underwriting Agreement, dated May 15, 2023, by and between Ikena Oncology, Inc. and Cowen and Company, LLC, as representative of the several underwriters named therein.

EX-1.1 2 d504516dex11.htm EX-1.1 Exhibit 1.1 IKENA ONCOLOGY, INC. 6,110,000 SHARES OF COMMON STOCK, $0.001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT May 15, 2023 COWEN AND COMPANY, LLC WILLIAM BLAIR & COMPANY, L.L.C. As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o William Blair & Company, L.L.C. 150 North Riverside Plaza

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A 1 d457446ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as

Schedule 14a

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Developing Biology-Driven Medicines and Expanding the Impact of Targeted Oncology • Multiple ongoing clinical trials with expected data readouts in the next 12 months • Leaders in Hippo pathway with clinical stage TEAD1 inhibitor IK-930 • Initial mon

EX-99.2 Exhibit 99.2 Corporate Presentation April 2023 Confidential 1 Developing Biology-Driven Medicines and Expanding the Impact of Targeted Oncology • Multiple ongoing clinical trials with expected data readouts in the next 12 months • Leaders in Hippo pathway with clinical stage TEAD1 inhibitor IK-930 • Initial monotherapy dose escalation data in all comers, mesothelioma, We develop differenti

Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual IK-930 is a potent Hippo-pathway inhibitor that selectiv

EX-99.1 Exhibit 99.1 Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting IK-930 is a potent Hippo-pathway inhibitor that selectively binds TEAD1 and broadly represses oncogenic TEAD signaling IK-930’s differentiated paralog selectivity and robust rep

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 IKENA ONCOLOGY, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40287 IKENA ONCOLOGY,

Amended & Restated Non-Employee Director Compensation Policy

EXHIBIT 10.4 IKENA ONCOLOGY, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Amended and Restated Non-Employee Director Compensation Policy (the “Policy”) of Ikena Oncology, Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or offi

As filed with the Securities and Exchange Commission on March 14, 2023

S-8 As filed with the Securities and Exchange Commission on March 14, 2023 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Ikena Oncology, Inc.

IKNA / Ikena Oncology, Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 2 TO THE SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Ikena Oncology, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45175G108 (CUSIP Number) Dec

IKNA / Ikena Oncology, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm233236-17sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Ikena Oncology, Inc (Name of Issuer) Common Stock, par value $0.001 per share (the “Shares”) (Tit

Ikena Oncology Appoints Owen Hughes as Board Chair Owen Hughes joins Ikena Board as independent director with operational and public company experience Ron Renaud steps down as he transitions into investment management role

Exhibit 99.1 Ikena Oncology Appoints Owen Hughes as Board Chair Owen Hughes joins Ikena Board as independent director with operational and public company experience Ron Renaud steps down as he transitions into investment management role BOSTON, Dec. 19, 2022 ? Ikena Oncology, Inc. (Nasdaq: IKNA, ?Ikena?), a targeted oncology company forging new territory in patient-directed cancer treatment, today

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 (December 14, 2022) IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorpo

Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update Novel best-in-class MEK-RAF complex inhibitor IK-595 targets RAS pathway; IND in 2023 Novel paralog-selective TEAD inhibitor IK-930 advancing as

EX-99.1 Exhibit 99.1 Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update Novel best-in-class MEK-RAF complex inhibitor IK-595 targets RAS pathway; IND in 2023 Novel paralog-selective TEAD inhibitor IK-930 advancing as planned in dose escalation; clinical data in 2023 Company prioritizes advancement of targeted oncology portfolio; cash runway ext

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2022 IKENA ONCOLOGY,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2022 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission

Developing Biology-Driven Medicines and Expanding the Impact of Targeted Oncology • Multiple ongoing clinical trials with expected data readouts in the next 12 months • Leaders in Hippo pathway with clinical stage paralog-selective TEAD inhibitor IK-

EX-99.2 Exhibit 99.2 Corporate Presentation Fourth Quarter 2022 Confidential 1 Developing Biology-Driven Medicines and Expanding the Impact of Targeted Oncology • Multiple ongoing clinical trials with expected data readouts in the next 12 months • Leaders in Hippo pathway with clinical stage paralog-selective TEAD inhibitor IK-930 We develop differentiated therapies • Initial mono-therapy in mesot

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 IKENA ONCOLOGY,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission

Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma IK-175 combined with nivolumab showed durable antitumor activity with a 20% ORR and 40% DCR in heavily pretreated urothelial carcinoma IK-175 monotherapy activ

EX-99.1 Exhibit 99.1 Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma IK-175 combined with nivolumab showed durable antitumor activity with a 20% ORR and 40% DCR in heavily pretreated urothelial carcinoma IK-175 monotherapy activity observed; confirmed partial response with DoR of 14.9 months and ongoing Program in collaboration with Bristol Myers Squibb a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40287 IKENA ONCOLOGY, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40287 IKENA ONCOLOGY, INC.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 (June 9, 2022) IKENA ONCOLOGY, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40287 IKENA ONCOLOGY, INC.

May 3, 2022

May 3, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confid

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

Sale Agreement, dated as of April 27, 2022, between the Registrant and Jefferies LLC

Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM April 27, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Ikena Oncology, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s common stoc

As filed with the Securities and Exchange Commission on April 27, 2022

Table of Contents As filed with the Securities and Exchange Commission on April 27, 2022 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Ikena Oncology, Inc.

Form of Subordinated Indenture between Registrant and one or more trustees to be named

Exhibit 4.6 IKENA ONCOLOGY, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Subordinated Debt Securities TABLE OF CONTENTS(1) Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Certif

Form of Senior Indenture between Registrant and one or more trustees to be named

Exhibit 4.5 IKENA ONCOLOGY, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Certifica

Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development Dr. Marango brings years of valued experience in oncology biopharma business, finance, and corporate relations & development

Exhibit 99.1 Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development Dr. Marango brings years of valued experience in oncology biopharma business, finance, and corporate relations & development BOSTON, April 13, 2022 ? Ikena Oncology, Inc. (Nasdaq: IKNA, ?Ikena?), a targeted oncology company forging new territory in patient-directed cancer treatment,

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2022 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission Fil

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2022 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40287 IKENA ONCOLOGY,

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Ikena Oncology, Inc.

As filed with the Securities and Exchange Commission on March 17, 2022

As filed with the Securities and Exchange Commission on March 17, 2022 Registration No.

Description of the Registrant’s securities registered pursuant to Section 12 of the Securities and Exchange Act of 1934, as amended (incorporated by reference to Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K (File No. 001-40287) filed on March 17, 2022).

Exhibit 4.3 Description of the Registrant?s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The following summary of the general terms and provisions of the registered capital stock Ikena Oncology, Inc. (?Ikena?, ?we?, ?our?) does not purport to be complete and is subject to, and qualified in its entirety by, reference to our Fifth Amended and Restat

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 (February 18, 2022) IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorpo

13G POWER OF ATTORNEY

13G CUSIP NO. 45175G108 Exhibit 99.2 POWER OF ATTORNEY Know all by these presents, that each of the undersigned hereby constitutes and appoints each other undersigned, such person?s true and lawful attorney-in-fact, to: (1) execute for and on behalf of each of such person Forms 3, 4, and 5 and Schedules 13D or 13G, as appropriate, and any required amendments thereto (collectively, the ?Reports?),

IKNA / Ikena Oncology, Inc. / Omega Fund VI, L.P. - SC 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 Ikena Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45175G108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Sta

IKNA / Ikena Oncology, Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 1 TO THE SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Ikena Oncology, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45175G108 (CUSIP Number) Dec

13G

13G CUSIP NO. 45175G108 Exhibit 99.1 AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Ikena Oncology, Inc. Dated: February 14, 2022 OMEGA FUND VI, L.P. BY: Omeg

IKNA / Ikena Oncology, Inc. / CITADEL ADVISORS LLC - IKENA ONCOLOGY, INC. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Ikena Oncology, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (the “Shares”) (Title of Class of Securities) 45175G108 (CUS

IKNA / Ikena Oncology, Inc. / Atlas Venture Fund X, L.P. - SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* IKENA ONCOLOGY, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 45175G108 (CUSIP Number) Atlas Venture Attention: Ommer Chohan, Chief Financial Officer 300 Technology Square, 8th Floor Cambridge, MA 02139 USA

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2022 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission F

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2022 (January 21, 2022) IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorpora

Ikena Appoints Richard Wooster, Ph.D., to its Board of Directors

Exhibit 99.1 Ikena Appoints Richard Wooster, Ph.D., to its Board of Directors BOSTON, Jan. 26, 2022 ? Ikena Oncology, Inc. (Nasdaq: IKNA, ?Ikena?), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced the appointment of Richard Wooster, Ph.D. to its Board of Directors. Dr. Wooster brings more than 30 years of experience in oncology drug discove

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40287 IKENA ONCOLOGY, INC.

November 2021

Exhibit 99.1 November 2021 Disclaimer This Presentation contains forward-looking statements and information. All statements other than statements of historical facts contained in this Presentation, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management and expected market size, are forward-looking stat

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated August 16, 2021, with respect to the ordinary shares of Ikena Oncology, Inc.

IKNA / Ikena Oncology, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Ikena Oncology, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 45175G108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Teleph

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40287 IKENA ONCOLOGY, INC.

Ikena Oncology Reports Second Quarter 2021 Financial Results and Provides Update on Key Programs IK-930 IND on track for submission in 2021; multiple upcoming preclinical and translational conference presentations on TEAD inhibition by IK-930 Progres

Exhibit 99.1 Ikena Oncology Reports Second Quarter 2021 Financial Results and Provides Update on Key Programs IK-930 IND on track for submission in 2021; multiple upcoming preclinical and translational conference presentations on TEAD inhibition by IK-930 Progressing IK-175 clinical trial monotherapy expansion cohort in bladder cancer patients Continued progress across targeted oncology pipeline t

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40287 IKENA ONCOLOGY, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission File

Ikena Oncology Reports First Quarter 2021 Financial Results and Outlines Key Corporate Objectives for 2021 Closed IPO and Raised $144 Million in Gross Proceeds to Fund Targeted Oncology Therapies IND Submissions for Lead Targeted Oncology Program, IK

Exhibit 99.1 Ikena Oncology Reports First Quarter 2021 Financial Results and Outlines Key Corporate Objectives for 2021 Closed IPO and Raised $144 Million in Gross Proceeds to Fund Targeted Oncology Therapies IND Submissions for Lead Targeted Oncology Program, IK-930, and BMS-partnered program, IK-412, Remain on Track for Second Half of 2021 Boston, MA ? May 13, 2021 ? Ikena Oncology, Inc. (Nasdaq

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Ikena Oncology, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 45175G108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-640

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated April 14, 2021, with respect to the ordinary shares of Ikena Oncology, Inc.

Ikena Oncology Appoints Dr. Maria Koehler to its Board of Directors

EX-99.1 Exhibit 99.1 Ikena Oncology Appoints Dr. Maria Koehler to its Board of Directors Boston, MA – April 15, 2021 – Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced the appointment of Maria Koehler, M.D., Ph.D. to its Board of Directors

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K 1 d135458d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2021 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of

March 30, 2021

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G*/ (Rule 13d-102) Ikena Oncology, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 45175G108 (CUSIP Number) March 30, 2021 Date of Event Which Requires Filing of the Statement Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ¨ Rul

JOINT FILING AGREEMENT

EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Ikena Oncology, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the unde

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. The undersigned also agree that

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated April 5, 2021 with respect to the shares of Common Stock, $0.001 par value per share of Ikena Oncology, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.__)* Ikena Oncology, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) (CUS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Ikena Oncology, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45175G108 (CUSIP Number) March 25, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Ikena Oncology, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45175G108 (CUSIP Number) Marc

Amended and Restated Bylaws of Ikena Oncology, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-40287) filed with the SEC on March 30, 2021).

Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF IKENA ONCOLOGY, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may su

- S-8

As filed with the Securities and Exchange Commission on March 30, 2021 Registration No.

Fifth Amended and Restated Certificate of Incorporation of Ikena Oncology, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40287) filed with the SEC on March 30, 2021).

Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IKENA ONCOLOGY, INC. Ikena Oncology, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is Ikena Oncology, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the S

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2021 IKENA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission Fil

7,812,500 Shares Common Stock

Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-253919 PROSPECTUS 7,812,500 Shares Common Stock We are offering 7,812,500 shares of common stock. This is our initial public offering of our common stock. Prior to this offering, there has been no public market for our shares. The initial public offering price is $16.00 per share. Our common stock has been approved for listing

VIA EDGAR

VIA EDGAR March 23, 2021 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

-

Jefferies LLC 520 Madison Avenue New York, New York 10022 Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, New York 10010 William Blair & Company, L.

Form 8-A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Ikena Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 81-1697316 (State of incorporation or organization) (I.R.S. Employer Identification No.) 645 Summer Street, Suit

Amended and Restated Bylaws of the Registrant (Incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-40287) filed with the Securities and Exchange Commission on March 30, 2021).

EXHIBIT 3.5 AMENDED AND RESTATED BY-LAWS OF IKENA ONCOLOGY, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may su

Form of Underwriting Agreement.

EXHIBIT 1.1 [Number of Shares] Ikena Oncology, Inc. UNDERWRITING AGREEMENT [Date] JEFFERIES LLC COWEN AND COMPANY, LLC CREDIT SUISSE SECURITIES (USA) LLC WILLIAM BLAIR & COMPANY, L.L.C. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o COWEN AND COMPANY, LLC 599 Lexington Avenue New York, New York 10022 c/o CREDIT SUISSE SECURITIES (US

2021 Stock Option and Incentive Plan, and form of award agreements thereunder (incorporated by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-253919) filed with the SEC on March 22, 2021).

EXHIBIT 10.2 IKENA ONCOLOGY, INC. 2021 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Ikena Oncology, Inc. 2021 Stock Option and Incentive Plan (as amended from time to time, the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Ikena Oncology, Inc. (the ?Co

- S-1/A

Table of Contents As filed with the Securities and Exchange Commission on March 22, 2021 Registration No.

Fifth Amended and Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40287) filed with the Securities and Exchange Commission on March 30, 2021).

EXHIBIT 3.3 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IKENA ONCOLOGY, INC. Ikena Oncology, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is Ikena Oncology, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the S

Certificate of Amendment of Fourth Amended and Restated Certificate of Incorporation of the Registrant.

Exhibit 3.2 CERTIFICATE OF AMENDMENT OF FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IKENA ONCOLOGY, INC. Ikena Oncology, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. The name of the Corporation is Ikena Oncology, Inc. The date of the

Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-253919) filed with the SEC on March 22, 2021).

Exhibit 4.1 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK PAR VALUE $.001 COMMON STOCK Certificate Number ZQ00000000 Ikena ONCOLOGY, INC. Shares **000000****************** ***000000**************** *****000000*************** *****000000****************** ******000000************** IKENA ONCOLOGY, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE THIS CERTIFIES THAT ** Mr

2021 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.3 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-253919) filed with the Securities and Exchange Commission on March 22, 2021).

EXHIBIT 10.3 IKENA ONCOLOGY, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Ikena Oncology, Inc. 2021 Employee Stock Purchase Plan (the ?Plan?) is to provide eligible employees of Ikena Oncology, Inc. (the ?Company?) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company?s common stock, par value $0.001 per share (the ?Common Stock

Form of Indemnification Agreement between the Registrant and each of its directors and executive officers (Incorporated by reference to Exhibit 10.5 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-253919) filed with the Securities and Exchange Commission on March 22, 2021).

EXHIBIT 10.5 IKENA ONCOLOGY, INC. FORM OF DIRECTOR INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of [ ] by and between Ikena Oncology, Inc., a Delaware corporation, together with its subsidiaries, (the ?Company?), and [Director] (?Indemnitee?). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indem

Non-Employee Director Compensation Policy.

EXHIBIT 10.4 IKENA ONCOLOGY, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the ?Policy?) of Ikena Oncology, Inc. (the ?Company?) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries (?

Form of Amended and Restated Employment Agreement (Incorporated by reference to Exhibit 10.6 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-253919) filed with the Securities and Exchange Commission on March 22, 2021).

EXHIBIT 10.6 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made between Ikena Oncology, Inc., a Delaware corporation (the ?Company?), and (the ?Executive?) and is effective as of the closing of the Company?s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the ?Effective

-

March 12, 2021 FOIA CONFIDENTIAL TREATMENT REQUEST The entity requesting confidential treatment is Ikena Oncology, Inc.

License Agreement by and between the Registrant and AskAt, Inc., dated December 14, 2017, as amended on December 18, 2018.

Exhibit 10.7 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. LICENSE AGREEMENT BY AND BETWEEN ARRYS THERAPEUTICS, INC. AND ASKAT, INC. TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 ARTICL

List of Subsidiaries of Registrant.

EX-21.1 12 d197729dex211.htm EX-21.1 Exhibit 21.1 Subsidiaries of Ikena Oncology, Inc. Name Jurisdiction of Incorporation or Organization Arrys Therapeutics, Inc. Delaware Amplify Medicines, Inc. Delaware Ikena Oncology Securities Corporation Massachusetts

Registration Statement - S-1

Table of Contents As filed with the Securities and Exchange Commission on March 5, 2021 Registration No.

Patent License Agreement by and between the Registrant and The University of Texas at Austin, on behalf of the Board of Regents of the University of Texas System, dated March 29, 2015, as amended on May 18, 2016, December 15, 2016, October 24, 2017, April 25, 2018 and January 9, 2019.

Exhibit 10.9 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. Patent License Agreement Agreement No. [***] This Patent License Agreement is between the Licensor and the Licensee identified

Master Collaboration Agreement by and between the Registrant and Celgene Corporation (now Bristol-Myers Squibb), dated January 14, 2019.

Exhibit 10.8 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. EXECUTION VERSION CONFIDENTIAL MASTER COLLABORATION AGREEMENT by and between CELGENE CORPORATION and KYN THERAPEUTICS INC. Date

Agreement and Plan of Merger by and among the Registrant, Arrys Merger Sub, Inc., Arrys Therapeutics, Inc. and OrbiMed Private Investments VI, LP, as stockholder representative, dated December 18, 2018.

Exhibit 2.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. AGREEMENT AND PLAN OF MERGER BY AND AMONG KYN THERAPEUTICS INC., ARRYS MERGER SUB, INC., ARRYS THERAPEUTICS, INC. AND ORBIMED PR

Fourth Amended and Restated Investors’ Rights Agreement, dated as of December 18, 2020 (incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-253919) filed with the SEC on March 22, 2021).

Exhibit 4.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. FOURTH AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT CONFIDENTIAL TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rig

Fourth Amended and Restated Certificate of Incorporation of Registrant, as currently in effect.

Exhibit 3.1 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IKENA ONCOLOGY, INC. Ikena Oncology, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. That the name of this corporation is Ikena Oncology, Inc., and that this corporation was original

2016 Stock Incentive Plan, and form of award agreements thereunder.

Exhibit 10.1 2016 STOCK INCENTIVE PLAN OF KYN THERAPEUTICS INC. TABLE OF CONTENTS Page 1. Purpose 1 2. Eligibility 1 3. Administration and Delegation 1 (a) Administration by the Board 1 (b) Appointment of Committees 1 4. Stock Available for Awards 2 (a) Number of Shares 2 (b) Substitute Awards 2 5. Stock Options 2 (a) General 2 (b) Incentive Stock Options 2 (c) Exercise Price 3 (d) Duration of Opt

Bylaws of Registrant, as currently in effect.

Exhibit 3.3 BYLAWS OF KYN THERAPEUTICS INC. (a Delaware corporation) i TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 2 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 3 1.10 Conduct of Meetings 3 1.11 Action without Meeting 4 ARTICLE II DIRECTORS 5 2.1 Gener

Agreement and Plan of Merger by and among the Registrant, AMI Merger Sub, Inc., Amplify Medicines, Inc. and Atlas Venture Fund XI, L.P. as stockholder representative, dated October 1, 2020.

Exhibit 2.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. AGREEMENT AND PLAN OF MERGER BY AND AMONG IKENA ONCOLOGY, INC. AMI MERGER SUB, INC. AMPLIFY MEDICINES, INC. AND ATLAS VENTURE FU

-

March 5, 2021 VIA EDGAR AND FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Mail Stop 4561 100 F Street, N.

Lease Agreement between the Registrant and OPG MP Parcel Owner (DE) LLC, dated July 31, 2020.

Exhibit 10.10 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. 645 SUMMER STREET BOSTON, MA LEASE AGREEMENT BETWEEN OPG MP PARCEL OWNER (DE) LLC, a Delaware limited liability company, AS LA

AGREEMENT AND PLAN OF MERGER BY AND AMONG IKENA ONCOLOGY, INC. AMI MERGER SUB, INC. AMPLIFY MEDICINES, INC. ATLAS VENTURE FUND XI, L.P. AS STOCKHOLDER REPRESENTATIVE

Exhibit 2.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. AGREEMENT AND PLAN OF MERGER BY AND AMONG IKENA ONCOLOGY, INC. AMI MERGER SUB, INC. AMPLIFY MEDICINES, INC. AND ATLAS VENTURE FU

-

Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 February 11, 2021 VIA EDGAR AND FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549 Attention: Kasey Robinson and Suzanne Hayes Re: Ikena Oncology, Inc. Draft Registration Statement on F

MASTER COLLABORATION AGREEMENT by and between CELGENE CORPORATION KYN THERAPEUTICS INC. Dated as of January 11, 2019

Exhibit 10.8 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. EXECUTION VERSION CONFIDENTIAL MASTER COLLABORATION AGREEMENT by and between CELGENE CORPORATION and KYN THERAPEUTICS INC. Date

2016 STOCK INCENTIVE PLAN KYN THERAPEUTICS INC.

Exhibit 10.1 2016 STOCK INCENTIVE PLAN OF KYN THERAPEUTICS INC. TABLE OF CONTENTS Page 1. Purpose 1 2. Eligibility 1 3. Administration and Delegation 1 (a) Administration by the Board 1 (b) Appointment of Committees 1 4. Stock Available for Awards 2 (a) Number of Shares 2 (b) Substitute Awards 2 5. Stock Options 2 (a) General 2 (b) Incentive Stock Options 2 (c) Exercise Price 3 (d) Duration of Opt